{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:53:47Z","timestamp":1784159627301,"version":"3.55.0"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>An inaugural set of consensus guidelines for malignancy screening in idiopathic inflammatory myopathy (IIM) were recently published by an international working group. These guidelines propose different investigation strategies based on \u201chigh\u201d, \u201cintermediate\u201d or \u201cstandard\u201d malignancy risk groups. This study compares current malignancy screening practices at an Australian tertiary referral center with the recommendations outlined in these guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of newly diagnosed IIM patients. Relevant demographic and clinical data regarding malignancy screening were recorded. Existing practice was compared with the guidelines using descriptive statistics; costs were calculated using the Australian Medicare Benefit Schedule.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 47 patients identified (66% female, median age: 63\u2009years [IQR: 55.5\u201370], median disease duration: 4\u2009years [IQR: 3\u20136]), only one had a screening\u2010detected malignancy. Twenty patients (43%) were at high risk, while 20 (43%) were at intermediate risk; the remaining seven (15%) had IBM, for which the proposed guidelines do not recommend screening. Only three (6%) patients underwent screening fully compatible with International Myositis Assessment and Clinical Studies recommendations. The majority (<jats:italic>N<\/jats:italic>\u2009=\u200939, 83%) were under\u2010screened; the remaining five (11%) overscreened patients had IBM. The main reason for guideline non\u2010compliance was the lack of repeated annual screening in the 3\u2009years post\u2010diagnosis for high\u2010risk individuals (0% compliance). The mean cost of screening was substantially lower than those projected by following the guidelines ($481.52 [SD 423.53] vs $1341 [SD 935.67] per patient), with the highest disparity observed in high\u2010risk female patients ($2314.29\/patient).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Implementation of the proposed guidelines will significantly impact clinical practice and result in a potentially substantial additional economic burden.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.15198","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:06:07Z","timestamp":1716275167000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world implications of <scp>IMACS<\/scp> malignancy screening guidelines for idiopathic inflammatory myopathies: An evaluation of compliance and economic impact at a tertiary referral center"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9649-5435","authenticated-orcid":false,"given":"Ian","family":"Teh","sequence":"first","affiliation":[{"name":"Department of Rheumatology The Royal Melbourne Hospital  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-1177","authenticated-orcid":false,"given":"Victoria","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology The Royal Melbourne Hospital  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-5711","authenticated-orcid":false,"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology The Royal Melbourne Hospital  Parkville Victoria Australia"},{"name":"The Walter and Eliza Hall Institute of Medical Research  Parkville Victoria Australia"},{"name":"The University of Melbourne  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-4361","authenticated-orcid":false,"given":"Jessica","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Rheumatology The Royal Melbourne Hospital  Parkville Victoria Australia"},{"name":"The Walter and Eliza Hall Institute of Medical Research  Parkville Victoria Australia"},{"name":"The University of Melbourne  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416665601"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09274.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3453-0"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1469-8"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.005"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01111-x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30956-0"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009639"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu289"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww024"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2011.tb03766.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.17061\/phrp2921913"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab166"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1745506520914804"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.15198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:12:14Z","timestamp":1716797534000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.15198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/1756-185X.15198"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.15198","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15198"}}